首页 > 最新文献

Recenti progressi in medicina最新文献

英文 中文
[Evidence shows superiority of triptans compared to both conventional and novel treatments in the management of acute migraine.] [有证据表明,在治疗急性偏头痛方面,曲坦类药物优于传统疗法和新型疗法。]
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44120
Peter K Kurotschka, David Slawson, Alice Serafini
{"title":"[Evidence shows superiority of triptans compared to both conventional and novel treatments in the management of acute migraine.]","authors":"Peter K Kurotschka, David Slawson, Alice Serafini","doi":"10.1701/4416.44120","DOIUrl":"https://doi.org/10.1701/4416.44120","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"53-54"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[How to report the end-of-life decisions in the clinical record? Proposal of an "ABCD".] 如何在临床记录中报告临终决定?“ABCD”的建议。]
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44116
Luigi Riccioni

Coping with the end of life decision making process in ICU, its complexity adds a challenge for the healthcare team: how to report in the medical record the events and reasoning that led to withholding or withdrawing treatments shifting from intensive to palliative care. Each healthcare team must select the best approach for managing the decision-making process and the necessary rules to ensure a correct clinical history narrative, indicating who must write and what has to be written. Taking into account the team organization, the report may be written not necessarily by the ICU director, but also by a staff physician as a spokesperson in the individual case. Regardless of the variability of each case, four points must be necessarily recorded recalling them with the first four letters of the alphabet (A, B, C, D) for an easier memorization: A= Anamnesis (clinical summary); B= Balancing (remodulation of care); C= Collegiality (sharing of decisions); D= Dialogue (conversation with the patient and/or family members).

在ICU中应对临终决策过程,其复杂性给医疗团队带来了挑战:如何在医疗记录中报告导致暂停或撤销治疗的事件和原因,从强化治疗转向姑息治疗。每个医疗团队必须选择管理决策过程的最佳方法和必要的规则,以确保正确的临床病史叙述,指示谁必须写和必须写什么。考虑到团队组织,报告可能不一定由ICU主任撰写,也可能由一名工作医师作为个案发言人撰写。无论每个病例的可变性如何,为了更容易记忆,必须记录四个点,用字母表的前四个字母(A, B, C, D)回忆它们:A=记忆(临床总结);B=平衡(调整);C=同僚关系(共同决策);D=对话(与病人和/或家属的对话)。
{"title":"[How to report the end-of-life decisions in the clinical record? Proposal of an \"ABCD\".]","authors":"Luigi Riccioni","doi":"10.1701/4416.44116","DOIUrl":"https://doi.org/10.1701/4416.44116","url":null,"abstract":"<p><p>Coping with the end of life decision making process in ICU, its complexity adds a challenge for the healthcare team: how to report in the medical record the events and reasoning that led to withholding or withdrawing treatments shifting from intensive to palliative care. Each healthcare team must select the best approach for managing the decision-making process and the necessary rules to ensure a correct clinical history narrative, indicating who must write and what has to be written. Taking into account the team organization, the report may be written not necessarily by the ICU director, but also by a staff physician as a spokesperson in the individual case. Regardless of the variability of each case, four points must be necessarily recorded recalling them with the first four letters of the alphabet (A, B, C, D) for an easier memorization: A= Anamnesis (clinical summary); B= Balancing (remodulation of care); C= Collegiality (sharing of decisions); D= Dialogue (conversation with the patient and/or family members).</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"42-46"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Prolonged cytopenia following third-line CAR-T therapy in a heavily chemotherapy-pretreated patient.] [一名重度化疗前患者三线CAR-T治疗后延长的细胞减少。]
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44126
Eugenio Galli

A 28-year-old woman was diagnosed with high-risk triple-expressor diffuse large B-cell lymphoma (DLBCL) (stage IV, IPI 4, CNS-IPI 5), with lymph node and extranodal involvement. The patient underwent first-line R-CHOP treatment, achieving a partial response with residual mediastinal uptake. A second-line platinum-based therapy with a transplant plan followed, resulting in stable disease; thus, she was considered refractory and started third-line therapy with CAR-T cells, receiving additional chemotherapy as bridging therapy. CAR-T treatment was well tolerated but complicated by late, persistent grade 4 cytopenia for over 2 years post-treatment, with complete and lasting lymphoma remission. Repeated chemotherapy exposure may predispose to acute and chronic toxicities, including cytopenia after CAR-T. If evaluated in 2024, the patient would have been considered for early access to CAR-T therapy, potentially reducing toxicity risks and improving event-free survival compared to conventional therapy.

一名28岁女性被诊断为高风险三表达弥漫性大b细胞淋巴瘤(DLBCL) (IV期,IPI 4, CNS-IPI 5),伴淋巴结和结外累及。患者接受了一线R-CHOP治疗,获得了部分缓解,纵隔摄取残留。随后进行了二线铂类药物治疗和移植计划,导致病情稳定;因此,她被认为是难治性的,开始使用CAR-T细胞进行三线治疗,并接受额外的化疗作为桥接治疗。CAR-T治疗耐受性良好,但治疗后2年多出现晚期持续性4级细胞减少症,淋巴瘤完全持久缓解。反复化疗暴露可能导致急性和慢性毒性,包括CAR-T后细胞减少。如果在2024年进行评估,患者将被考虑早期接受CAR-T治疗,与传统治疗相比,可能降低毒性风险并提高无事件生存率。
{"title":"[Prolonged cytopenia following third-line CAR-T therapy in a heavily chemotherapy-pretreated patient.]","authors":"Eugenio Galli","doi":"10.1701/4416.44126","DOIUrl":"https://doi.org/10.1701/4416.44126","url":null,"abstract":"<p><p>A 28-year-old woman was diagnosed with high-risk triple-expressor diffuse large B-cell lymphoma (DLBCL) (stage IV, IPI 4, CNS-IPI 5), with lymph node and extranodal involvement. The patient underwent first-line R-CHOP treatment, achieving a partial response with residual mediastinal uptake. A second-line platinum-based therapy with a transplant plan followed, resulting in stable disease; thus, she was considered refractory and started third-line therapy with CAR-T cells, receiving additional chemotherapy as bridging therapy. CAR-T treatment was well tolerated but complicated by late, persistent grade 4 cytopenia for over 2 years post-treatment, with complete and lasting lymphoma remission. Repeated chemotherapy exposure may predispose to acute and chronic toxicities, including cytopenia after CAR-T. If evaluated in 2024, the patient would have been considered for early access to CAR-T therapy, potentially reducing toxicity risks and improving event-free survival compared to conventional therapy.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"8e-11e"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Linfoma diffuso a grandi cellule in terza linea (e oltre). 第三行(及以上)弥漫性大细胞淋巴瘤。
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44124
Alessandro Broccoli, Pier Luigi Zinzani
{"title":"Linfoma diffuso a grandi cellule in terza linea (e oltre).","authors":"Alessandro Broccoli, Pier Luigi Zinzani","doi":"10.1701/4416.44124","DOIUrl":"https://doi.org/10.1701/4416.44124","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"1e-3e"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Tirzepatide reduces body weight and improves symptoms in patients with obstructive sleep apnea syndrom.] [替西肽可减轻阻塞性睡眠呼吸暂停综合征患者的体重并改善症状。]
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44118
Viviana Forte, Mark H Ebell, Peter K Kurotschka
{"title":"[Tirzepatide reduces body weight and improves symptoms in patients with obstructive sleep apnea syndrom.]","authors":"Viviana Forte, Mark H Ebell, Peter K Kurotschka","doi":"10.1701/4416.44118","DOIUrl":"https://doi.org/10.1701/4416.44118","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"49-50"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Access requirements for medically assisted death: an open question.] [医疗辅助死亡的准入要求:一个悬而未决的问题。]
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44113
Lucia Craxì

The commentary focuses on the requirements for access to medical assistance in dying in countries where this practice is legal. It shows that the different solutions adopted reflect a different balance between the principles of protection of life, reduction of suffering and respect for autonomy. The article also analyses the potential ethical problems associated with the decision-making capacity of psychiatric patients. It emphasizes the need to assess the capacity on a case-by-case basis, without a priori excluding those suffering from mental disorders. It then examines the nature of existential suffering as a potential single condition for access to medical assistance in dying, highlighting its relevant ethical and social implications.

评注的重点是在这种做法合法的国家,在死亡时获得医疗援助的要求。它表明,所采取的不同解决办法反映了保护生命、减少痛苦和尊重自治原则之间的不同平衡。文章还分析了与精神病患者决策能力相关的潜在伦理问题。它强调有必要在个案基础上评估能力,而不是先验地排除患有精神障碍的人。然后,它审查了作为在死亡中获得医疗援助的潜在单一条件的存在痛苦的性质,强调了其相关的伦理和社会影响。
{"title":"[Access requirements for medically assisted death: an open question.]","authors":"Lucia Craxì","doi":"10.1701/4416.44113","DOIUrl":"https://doi.org/10.1701/4416.44113","url":null,"abstract":"<p><p>The commentary focuses on the requirements for access to medical assistance in dying in countries where this practice is legal. It shows that the different solutions adopted reflect a different balance between the principles of protection of life, reduction of suffering and respect for autonomy. The article also analyses the potential ethical problems associated with the decision-making capacity of psychiatric patients. It emphasizes the need to assess the capacity on a case-by-case basis, without a priori excluding those suffering from mental disorders. It then examines the nature of existential suffering as a potential single condition for access to medical assistance in dying, highlighting its relevant ethical and social implications.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Muscle relaxants: uncertain risk-benefit balance in chronic pain syndromes.] [肌肉松弛剂:慢性疼痛综合征的不确定风险-收益平衡。]
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44121
Peter K Kurotschka, David Slawson, Alice Serafini
{"title":"[Muscle relaxants: uncertain risk-benefit balance in chronic pain syndromes.]","authors":"Peter K Kurotschka, David Slawson, Alice Serafini","doi":"10.1701/4416.44121","DOIUrl":"https://doi.org/10.1701/4416.44121","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"55-56"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dalla letteratura
2025 Gennaio.
2025年1月。
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44112
{"title":"Dalla letteratura<br> 2025 Gennaio.","authors":"","doi":"10.1701/4416.44112","DOIUrl":"https://doi.org/10.1701/4416.44112","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"2-8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Professionals in the care of the end of life: plurality of postures.] [临终关怀的专业人士:多种姿势。]
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44114
Sandro Spinsanti

Deciding what type of health professional to be: the postural profile that is assumed in the care relationship is born from this challenge. These postures have a profound impact on the way in which care for the patient and end-of-life decisions will be developed. Broadly speaking, we can distinguish five macro postural profiles: the scientistic posture (the natural sciences are the only guide for the professional); the vitalist posture (the goal of saving the patient's life at all costs); the specialist posture (fragmentation of care managed by multiple specialists); the philanthropic posture (in which empathetic closeness to the patient prevails); the conversational posture (care "with" the patient, not "on" him). In light of this, it is essential to become aware of how you want to treat yourself and how you want to be treated, choosing, as far as possible, the appropriate travel companions.

决定成为哪种类型的健康专业人员:在护理关系中假设的姿势轮廓就来自于这个挑战。这些姿势对病人的护理和临终决定的制定有着深远的影响。从广义上讲,我们可以区分出五种宏观姿态:科学主义姿态(自然科学是专业人士的唯一指南);生机论者的姿态(不惜一切代价挽救病人生命的目标);专家姿态(由多名专家管理的分散护理);慈善的姿态(在这种姿态中,对病人感同身受);谈话的姿势(“和”病人一起,而不是“在”他身上)。考虑到这一点,有必要意识到你希望如何对待自己,以及你希望别人如何对待你,尽可能选择合适的旅伴。
{"title":"[Professionals in the care of the end of life: plurality of postures.]","authors":"Sandro Spinsanti","doi":"10.1701/4416.44114","DOIUrl":"https://doi.org/10.1701/4416.44114","url":null,"abstract":"<p><p>Deciding what type of health professional to be: the postural profile that is assumed in the care relationship is born from this challenge. These postures have a profound impact on the way in which care for the patient and end-of-life decisions will be developed. Broadly speaking, we can distinguish five macro postural profiles: the scientistic posture (the natural sciences are the only guide for the professional); the vitalist posture (the goal of saving the patient's life at all costs); the specialist posture (fragmentation of care managed by multiple specialists); the philanthropic posture (in which empathetic closeness to the patient prevails); the conversational posture (care \"with\" the patient, not \"on\" him). In light of this, it is essential to become aware of how you want to treat yourself and how you want to be treated, choosing, as far as possible, the appropriate travel companions.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"14-19"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical decision rules for chest pain in primary care are supported by weak evidence and are difficult to apply.] [初级保健胸痛的临床决策规则证据不足,难以应用。]
Q3 Medicine Pub Date : 2025-01-01 DOI: 10.1701/4416.44119
Viviana Forte, Henry Barry, Peter K Kurotschka
{"title":"[Clinical decision rules for chest pain in primary care are supported by weak evidence and are difficult to apply.]","authors":"Viviana Forte, Henry Barry, Peter K Kurotschka","doi":"10.1701/4416.44119","DOIUrl":"https://doi.org/10.1701/4416.44119","url":null,"abstract":"","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 1","pages":"51-52"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Recenti progressi in medicina
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1